Senesco submits IND for multiple myeloma drug
Senesco was previously granted orphan drug status for SNS01-T. Senesco plans to evaluate SNS01-T in patients with relapsed or refractory disease who have failed at least two standard
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.